Factor IXa inhibitors as novel anticoagulants.
Arterioscler Thromb Vasc Biol
; 27(4): 722-7, 2007 Apr.
Article
en En
| MEDLINE
| ID: mdl-17272750
ABSTRACT
Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced thrombophilia. Because factor IX plays a pivotal role in tissue factor (TF)-mediated thrombin generation, it may represent a promising target for drug development. Several methods of attenuating factor IX activity, including monoclonal antibodies, synthetic active site-blocked competitive inhibitors, oral inhibitors, and RNA aptamers, have undergone investigation. This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Factor IXa
/
Anticoagulantes
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Arterioscler Thromb Vasc Biol
Asunto de la revista:
ANGIOLOGIA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Estados Unidos